Table 1 Patient characteristics at baseline
Variable | n |
|---|---|
Patients | 35 |
Median age years (range) | 64 (40–75) |
Menopause | |
Pre | 9 |
Post | 26 |
ECOG PS | |
0 | 28 |
1 | 7 |
Hormone receptor | |
Positive | 28 |
Negative | 7 |
Stage | |
Inoperable | 14 |
Recurrent | 21 |
Neoadjuvant/adjuvant chemotherapy | |
Yes | 15 |
No | 20 |
Prior anthracycline | 10 |
Prior taxanes | 9 |
No. of metastatic sites | |
1 | 17 |
2 | 12 |
3 | 5 |
4 | 1 |
Metastatic site | |
Lung | 17 |
Bone | 12 |
Liver | 7 |
Lymph node | 12 |
Pleura | 3 |
Skin | 2 |
Adrenal | 1 |
Treatment exposure, cycles (range) | 8 (1–21) |
Dose reduction | |
Yes | 4 |
No | 31 |
Schedule modification | |
Yes | 19 |
No | 16 |